Th e data presented by Schochl and colleagues will be seen as intriguing, important, innovative, and controversial [1] . Th is paper builds on work by Dr Detmer Fries, published in a swine injury model in 2006 [2, 3] . However, as with all retrospective studies, caution must be exercised before widespread adoption. Th e usual concerns apply as there is no control group, the data supporting the thromboelastometry goal-directed algorithm are not presented, and the risks of using and combining fi brinogen concentrates and plasma complex concen trates (PCCs) in trauma patients are unknown. Preclinical and clinical evidence to answer these questions is lacking and should be investigated.
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With regards to the study by Schochl and colleagues, I am concerned with the comparison of mortality rates in the small numbers of seriously injured patients collected over 5 years to that predicted by the trauma injury severity score (TRISS) and by the revised injury severity classifi cation (RISC) score. It is very easy for such small data sets to suff er signifi cant statistical problems when attempting to match injuries and initial physiology. It would have been preferable to at least construct a before and after design. Several questions are apparent: when the thromboelastometry was repeated, did the test results change (improve?) after transfusion of the proscribed agent? What was the timing of the fi brinogen and PCC concentrates in relation to red blood cells (RBCs)? How often was the fi brinogen or PCC given before the RBCs? How did mortality change over time, as the authors became more comfortable with their alternative resuscitation strategy?
Despite these and many more questions, I sincerely congratulate the authors on forging ahead and intro ducing a novel resuscitation approach. Th e issues inherent in this retrospective study (and in every one of the recently published retrospective transfusion studies, including ours [4] ) are signifi cant and will only be resolved when prospective studies are fi nally performed. As an aside, this standard comment leads me to wonder why we must have level I data to change traditional practice, when the current transfusion traditions are based on small, uncontrolled, rarely read, retrospective studies utilizing blood products no longer available. Tradition is recognized as the hardest thing to change, and the recent and now numerous transfusion studies in seriously injured patients are arguably leading the way in a wholesale revolution in transfusion medicine. It seems that physiology is starting to take precedence over tradition in this area, and other specialties are taking notice.
We now recognize that fully one-third of transfused patients are coagulopathic. For years, in seriously injured trauma patients suff ering hemorrhagic shock, we fi rst gave multiple varieties of salt solutions, followed by RBCs. Th ere was an ongoing controversy about crystalloid versus colloid; these resuscitation fl uids increase coagulation problems and neither increase oxygen delivery. Only after liters of these fl uids were transfused were components that both increased intravascular volume and helped reverse coagulopathy fi nally delivered. Now, many centers are giving early and increased amounts of plasma proteins and platelets. At our center we more frequently give plasma before RBCs in our seriously injured trauma patients that suff er hemorrhagic shock. Anecdotally, this change in practice has been associated with less bleeding, improved survival, decreased edema and lowered multiple organ failure rates. Th e mechanism accounting for these clinical observations remains to be elucidated [5, 6] . We feel that many of these products not only replace coagulation factors, facilitating early cessation of bleeding, and provide eff ective volume resuscitation, but more importantly stabilize the endothelium, reverse the early coagulopathy of trauma, reverse endothelial permeability, decrease edema and repair the endothelium, thus preventing early onset of multiple organ failure related to resuscitation injury. Th e thousands of proteins present in platelets and plasma certainly 'do more than' just replace the few coagulation proteins we commonly measure.
Th e transfusion method of Schochl and colleagues appears to be more physiologic and data driven when compared to the tradition-motivated approach to resuscitation of the severely injured trauma patient in hemorrhagic shock. More studies like this will soon see the light of publication and form the basis for a revolution in transfusion therapy over the next decade. I think that commercial entities should take note, as their approach will certainly open new markets and opportunities.
Current blood banks are largely focused on logistical issues of shelf life, avoiding disease transmission, and the immunologic consequences of liquid transfusion. Th ey have been very successful in managing these issues. However, there have been very few well designed studies over the past 30 years in the transfusion literature describ ing any clinical improvements after transfusion in trauma patients. No quality data from studies in trauma patients are available for current blood products. Amazingly, there is no requirement to have clinical outcome data when modifi cations to currently approved blood products are introduced. Injury has been recognized as causing more than 5 million deaths worldwide and is listed as a major global issue by the WHO [7] . It is time for blood banks to evolve [8] . It is easy to anticipate a separation of emergency transfusion in rapidly bleeding patients from the traditional blood bank over the next decade, with dried blood products/proteins utilized in a point of care mode, stored in the clinical areas where the patients are cared for (including the pre-hospital environment), and resuscitation based upon laboratory data available within minutes that guide protein-specifi c infusion. It will be nice to only transfuse what is needed, based on level I data, fi nally balancing risk and benefi t in a data-driven fashion for the benefi t of our patients. Th e paper by Schochl and colleagues is a step in that direction.
Abbreviations PCC = plasma complex concentrate; RBC = red blood cell.
